DXNVX, Smooth Progress in Expanding Global New Drug Pipeline Development
KOSDAQ-listed company Dx&Vx announced on the 16th that with the addition of world-renowned infectious disease expert Professor Namjun Cho, it will participate in the 'Disease X' response project led by him, currently being conducted at Stanford University and the U.S. National Institutes of Health (NIH).
'Disease X' is a project led by Professor Namjun Cho, supported by the U.S. National Institutes of Health (NIH) and Stanford University, receiving a total funding of $2.23 million to be carried out until 2027.
Professor Cho, who is a Chair Professor at Nanyang Technological University in Singapore and also serves as the project leader of the Antiviral Drug Discovery Centers for Pathogens of Pandemic Center at Stanford School of Medicine, stated, "I sympathize with CEO Jongyun Lim’s goal of 'commercializing everything related to microbes,' and decided to join Dx&Vx to realize this vision together."
The new drugs being developed at Stanford University and affiliated companies consist of innovative technologies and substances necessary to prevent and treat previously unknown viral pandemics, with plans to license technology for at least three or more substances.
These technologies will first be licensed to Dx&Vx, and subsequently, through collaboration with Hanmi Pharmaceutical Group and Kori Group, the company plans to accelerate project commercialization and the development of a global new drug pipeline.
A Dx&Vx representative stated, "To commercialize the project, we plan to accelerate the introduction of innovative infectious disease vaccine manufacturing technologies through close cooperation with Hanmi Pharmaceutical Group and Kori Group, and speed up the expansion of infectious disease vaccine development infrastructure to prepare for the future 'Disease X'."
Hot Picks Today
"I Went for the Cheap Coffee, but Now I Feel Uneasy"... Major Coffee Franchises Cited for Violations One After Another
- In Korea, Studying Medicine Is in High Demand, but in China, It's Shunned: "Why Become a Doctor When You Can’t Make Money?"
- "Surprisingly Real, Perfect Like AI" -- Global Media Praise Korean Fencer's Beauty
- "50 Million Won for Weekly Encounters"... Man in His 60s Sentenced for Deceiving Woman in Her 20s with Forged 1.4 Billion Won Account
- "I've Already Booked My Trip to Japan, But This Is Serious"...Highest Number of Measles Cases in Japan in a Decade Spurs Emergency Alert
In particular, the representative added, "Regarding obesity treatments, which have recently attracted significant global market interest, we are currently preparing early patent applications for multiple substances and will concurrently conduct additional studies such as animal testing."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
